Interferon alfa 2b is an antiviral drug originally discovered in the laboratory of Charles Weissmann at the University of Zurich, developed at Biogen, and ultimately marketed by Schering-Plough under the tradename Intron-A. It has been used for a wide range of indications, including viral infections and cancers.
This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.
See also [edit]
References [edit]
- ^ Dmitrij I. Bairamashvili1 and Mikhail L. Rabinovich2* (2007). "Russia through the prism of the world biopharmaceutical market". Biotechnol. J 2.
External links [edit]
|
|
|
| By family |
|
|
By function/
cell |
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
|
|
|
| Endogenous |
|
|
|
|
|
Other protein / peptide
|
|
|
|
Other
|
|
|
|
| Exogenous |
|
|
|
|
|
|
|
|
| Baltimore I |
|
|
|
DNA-synthesis
inhibitor
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hepatitis B (VII) |
|
|
| Multiple/general |
|
Nucleic acid inhibitors
|
|
|
|
|
|
|
|
Multiple/unknown
|
|
|
|
|
|
|
(what is this?) (verify)
